Partners
Qureight
Lead Partner
Qureight is techbio company based in Cambridge UK. Founded by doctors and scientists it aims to be THE data platform for lung and heart disease. It structures data from health care and biopharma partners to find new endpoints, speed up clinical trials and help bring drugs to the market. By analysing data on it’s cloud based platform, Qureight allows collaborators to build machine learning models to better understand diseases. It has a current focus in IPF, ILD, Pulmonary Hypertension and Lung Cancer. It recently published a landmark paper in AJRCCM detailing 4 deep learning imaging models in IPF.
FibroFind Bio
Expertise Partner
FibroFind specialises in the application of advanced technologies for interrogating fibrosis biology. Leveraging our expertise, we have developed proprietary bioreactor-cultured precision-cut tissue slices (PCTS) that demonstrate exceptional performance in biomarker identification, toxicology, target discovery and drug efficacy evaluation.
By harnessing robotics, AI-guided data analysis and a highly skilled team, FibroFind ensures unparalleled quality in all studies. Our portfolio includes PCTS from healthy and diseased (IPF, ILD, COPD) lungs, in 24 and 96 well formats, allowing us to customise studies to meet your specific needs and deliver results that drive your research forward
Nordic
Expertise Partner
Nordic Bioscience is a biotech company founded in 1992 located in Herlev, Denmark. Nordic Bioscience is focused on the development, testing and validation of new blood based biochemical markers for diagnosis and prognosis of fibrotic and inflammatory diseases. We are a science-driven company that invests heavily in developing blood-based precision medicine solutions for the pharmaceutical industry as well as for patient care through our research and development division. Our central laboratory division offers a complete portfolio of central laboratory services as well as novel biomarker measures.
OSIC ILD
Expertise Partner
Open Source Imaging Consortium (OSIC) – a global 501(c)(3), not‑for‑profit cooperative effort between academia, industry and patient advocacy groups – was created to look at lung diseases differently, and to drive collaboration between unlikely partners. Our goal is to make rapid, open source advances in the detection and diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) for the countless patients and their caregivers living with these diseases. OSIC is a global effort using real-world curated data machine learning & collaboration to fight ILDs.
Vitalograph
Hosting Partner
Vitalograph provides sponsors with everything needed to collect, QC, and report on Respiratory endpoint data for the following assessments: FEV1, FVC, SVC, PEF, ECG, ePRO/ eCOA, FeNO, DLCO, 6MWT, and objective cough counting. Our knowledgeable and responsive teams of dedicated project and data managers, clinical respiratory physiologists, cough analysts, software development engineers, in-house QA and logistic specialists, plus highly experienced site support staff, are what make our innovative and personalized solutions possible.
4DMedical (Imbio)
Hosting Partner
4DMedical is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.
In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio’s regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalized care for patients.
Brainomix
Program Partner
Brainomix specializes in the creation of clinically available AI powered software solutions to enable precision medicine for better treatment decisions. With origins as a spin-out from the University of Oxford, Brainomix developed the world's first AI-powered software for stroke assessment and is now an expanding commercial-stage company with offices in the UK, Ireland and the USA. Brainomix has operations in more than 30 territories, including a number of competitively awarded country-wide deployments to achieve complete national coverage with it's AI software. Brainomix's e-Lung technology and suite of AI-powered quantitative imaging biomarkers are currently utilised by sponsors to support the development and commercialisation of treatments for interstitial lung disease, both during clinical research and in real-world clinical practice.
Mannkind
Industry Partner
MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, IPF, PAH and NTM lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
Fortrea
Innovation Partner
Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.
Strados
Exhibition Partner
Strados Labs partners with IPF drug developers to collect real-world, objective measures of subjects’ cough and lung health to complement subjective patient self-reporting. Using a combination of audio and motion data, the RESP® Biosensor remotely and continuously captures coughing and lung sounds including crackles as well as respiratory rate, activity levels, and sleep/wake to offer stronger insight into treatment response. Designed for daily life, the RESP Biosensor is wireless, discreet and doesn’t interfere with daily routines. The biosensor has 2 FDA 510(k) clearances, a CE mark and is used in clinical trials across 4 continents.
IPS Therapeutique
Exhibition Partner
IPST’s tradition of collaboration and innovation has led to success through association, a foot planted in scientific discovery, the other in the reality of drug development. By combining functional readouts with biomarkers and histology, IPST’s fibrosis models, with pulmonary fibrosis at the forefront, have successfully supported preclinical and clinical candidates for almost a decade.
Q2 Solutions
Exhibition Partner
Rules-Based Medicine (RBM), a Q2 Solutions company, provides specialty immunoassay testing that solves complex drug development challenges. RBM offers one of the most comprehensive menus of quantitative protein biomarkers, including multiplexed immunoassays (Luminex®) and ultrasensitive immunoassays. RBM offers a suite of internally developed and validated biomarkers to support new therapies for idiopathic pulmonary fibrosis (IPF). Chosen in collaboration with the Prognostic Lung Fibrosis Consortium (PROLIFIC), these markers have utility in characterizing epithelial damage, fibrosis, inflammation and thrombosis.
Aragen Life Sciences
Exhibition Partner
Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. Aragen offers end-to-end integrated or standalone solutions to advance small and large molecule programs from concept to commercialization. Established in 2001, the Company operates through a global network of six sites with a team of 3800+ employees and 450+ PhDs. Its expertise and experience have enabled over 450 customers (including 7 of the top 10 pharma companies globally) in advancing their research programs from early discovery through development and commercialization. Aragen’s innovative mindset, infrastructure, flexible business models, a clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech,
agrochemical, and animal health industries globally.
Clario
Event Partner
Clario is a leading healthcare research and technology company that generates the highest quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence-generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario’s science, technology, and operational experts have helped deliver over 26,000 trials and contributed to over 800 regulatory approvals in more than 100 countries. For more than 50 years, we have provided deep scientific expertise and the broadest endpoint technologies to help transform lives around the world
Newcells Biotech
Event Partner
Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. We build functional in vitro models of the kidney, retina and lung to improve clinical translation and drug discovery. By applying our expertise in induced pluripotent stem cells (iPSCs), primary tissues, a deep understanding of cellular physiology and organoid technology, we have built validated models and assays that have proven to be predictive of how drugs interact with tissues and organs.
Ionis
Industry Partner
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
FIND OUT MORE ABOUT OUR PARTNERSHIP OPPORTUNITIES
